David Brocks
Overview
Explore the profile of David Brocks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, et al.
Cancer Cell
. 2024 Aug;
42(9):1582-1597.e10.
PMID: 39214097
Combination checkpoint blockade with anti-PD-1 and anti-CTLA-4 antibodies has shown promising efficacy in melanoma. However, the underlying mechanism in humans remains unclear. Here, we perform paired single-cell RNA and T ...
2.
Jain N, Zhao Z, Koche R, Antelope C, Gozlan Y, Montalbano A, et al.
Cancer Discov
. 2023 Nov;
14(1):142-157.
PMID: 37934007
Significance: T cells engineered with CD28-based CARs possess robust effector function and antigen sensitivity but are hampered by limited persistence, which may result in tumor relapse. We report an epigenetic...
3.
ONeill K, Brocks D, Gale Hammell M
Philos Trans R Soc Lond B Biol Sci
. 2020 Feb;
375(1795):20190345.
PMID: 32075565
Next-generation sequencing approaches have fundamentally changed the types of questions that can be asked about gene function and regulation. With the goal of approaching truly genome-wide quantifications of all the...
4.
Goeppert B, Toth R, Singer S, Albrecht T, Lipka D, Lutsik P, et al.
Hepatology
. 2019 Jan;
69(5):2091-2106.
PMID: 30615206
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer. It is defined by cholangiocytic differentiation and has poor prognosis. Recently, epigenetic processes have been shown to play an...
5.
Blagitko-Dorfs N, Schlosser P, Greve G, Pfeifer D, Meier R, Baude A, et al.
Leukemia
. 2018 Nov;
33(4):945-956.
PMID: 30470836
DNA methyltransferase inhibitors (DNMTi) approved for older AML patients are clinically tested in combination with histone deacetylase inhibitors (HDACi). The mechanism of action of these drugs is still under debate....
6.
Daskalakis M, Brocks D, Sheng Y, Islam M, Ressnerova A, Assenov Y, et al.
Cell Cycle
. 2018 Apr;
17(7):811-822.
PMID: 29633898
Inhibitors of DNA methyltransferases (DNMTis) or histone deacetylases (HDACis) are epigenetic drugs which are investigated since decades. Several have been approved and are applied in the treatment of hematopoietic and...
7.
Assenov Y, Brocks D, Gerhauser C
Semin Cancer Biol
. 2018 Jan;
51:12-21.
PMID: 29366906
Analogous to life on earth, tumor cells evolve through space and time and adapt to different micro-environmental conditions. As a result, tumors are composed of millions of genetically diversified cells...
8.
Lipka D, Witte T, Toth R, Yang J, Wiesenfarth M, Nollke P, et al.
Nat Commun
. 2017 Dec;
8(1):2126.
PMID: 29259247
Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative disorder of early childhood characterized by mutations activating RAS signaling. Established clinical and genetic markers fail to fully recapitulate the clinical and...
9.
Brocks D, Schmidt C, Daskalakis M, Jang H, Shah N, Li D, et al.
Nat Genet
. 2017 Oct;
49(11):1661.
PMID: 29074949
This corrects the article DOI: 10.1038/ng.3889.
10.
Brocks D, Schmidt C, Daskalakis M, Jang H, Shah N, Li D, et al.
Nat Genet
. 2017 Jun;
49(7):1052-1060.
PMID: 28604729
Several mechanisms of action have been proposed for DNA methyltransferase and histone deacetylase inhibitors (DNMTi and HDACi), primarily based on candidate-gene approaches. However, less is known about their genome-wide transcriptional...